Cambridge, United Kingdom · Est. 1913 · 89,000 employees
Global biopharmaceutical company focused on prescription medicines.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 15 drugs with upcoming expirations
Pipeline
By Phase
195 drugs in development
By Therapeutic Area
top 6
R&D Momentum
100/100
Pipeline Velocity
100/100
Trial Completion Rate
88/100
Pipeline Concentration
29/100
Pipeline Freshness
69/100
Strategic Signals
Activity
Last 14 days
A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
The Eplontersen Pregnancy and Lactation Outcomes Study (EPPRO): A Descriptive Safety Study of Pregnant and Lactating Individuals and Their Offspring Exposed to Eplontersen
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Metastatic Solid Tumors That Are MTAP Deficient
A Phase III, Multicentre, Open-Label, Chronic Dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)
A Participant- and Investigator-blind, Randomized, Placebo-controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair With AZD7798 in Patients With Active Ileal Crohn's Disease and an Ileostomy (CALLISTO)
A French Multicentric Observational Study of Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia Patients
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
A Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating AstraZeneca (or Alliance Developed) Drugs
A Multicenter Pilot Study to Investigate Ocular Involvement and the Potential of Ocular Imaging for Non-invasive Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
A Randomised, Double-blind, Placebo-controlled, Multi-centre, Sequential Phase II, and Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 Administered for up to 52 Weeks in Participants With Dyslipidaemia (AZURE-CHINA)
Details
Company Overview
$240.0B
Mkt Cap
$45.8B
Revenue
$6.9B
Cash
Therapeutic Focus
Pipeline
Regulatory
Saphnelo — SAPHNELO
Application BLA761123 (BLA)
Lynparza — LYNPARZA
Application NDA208558
Lynparza — LYNPARZA
Application NDA208558
Imjudo — IMJUDO
Application BLA761289 (BLA)
Lynparza — LYNPARZA
Application NDA208558
Calquence — CALQUENCE
Application NDA216387 (NDA)
Lynparza — LYNPARZA
Application NDA208558
Lynparza — LYNPARZA
Application NDA208558
Wainua (autoinjector) — WAINUA (AUTOINJECTOR)
Application NDA217388 (NDA)
Daliresp — ZORYVE
Application NDA217242 (NDA)
Truqap — TRUQAP
Application NDA218197 (NDA)
Lynparza — LYNPARZA
Application NDA208558
Lynparza — LYNPARZA
Application NDA208558
Lynparza — LYNPARZA
Application NDA208558
Daliresp — ZORYVE
Application NDA215985 (NDA)
Fabhalta — VOYDEYA
Application NDA218037 (NDA)
Koselugo — KOSELUGO
Application NDA219943 (NDA)
Lynparza — LYNPARZA
Application NDA208558
Baxfendy — BAXFENDY
Application NDA219878 (NDA)
Saphnelo — SAPHNELO
Application BLA761451 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)